Industries

Lendlease has lost its appeal of a ruling that shot down its bid to enforce a $120 million purchase agreement for five plots of land in Campbelltown against a company controlled by the Macarthur-Onslow family. 

An iProsperity director must pay $5.3 million to ZACD for his conduct in convincing the Singapore-based real estate investment firm to cough up $37.5 million for its $300 million purchase of the AccorInvest hotels portfolio.

Canberra developer Geocon has won a Full Court appeal over the GST payable on $115 million in sales from a 360-unit development, with the case sent back to a tribunal for final determination.

Carlisle Homes has prevailed on a preliminary question in a dispute with Nexus Office over alleged defects in a Nexus Mulgrave rental space, with an appeals court finding an expert had not properly determined the dispute. 

Charter Hall has acquired the Burwood One shopping centre in Melbourne’s east for $210 million, just days after snapping up a triple-supermarket-anchored shopping destination in Queensland. 

Special purpose liquidators have been appointed to failed clothing retailer Mosaic Brands, after a judge found a reasonable apprehension of bias arising from liquidator Vaughan Strawbridge's former link to Deloitte.

Woolworths has been hit with a shareholder class action for underpaying workers hundred of millions of dollars, with investors alleging the supermarket giant issued inflated financial statements by failing to account for proper staff remuneration. 

Car dealership software firm Pentana has accused competitor Titan of a "calculated, sustained and brazen" invasion of its rights, and argues cross-claims of misuse of market power are a distraction.

Grand Ridge Plantations has lost an appeal seeking to halve the official valuation of its Gippsland timber forest, with a court finding that the trees on the land must be included in its assessed value.

The Full Federal Court has upheld a decision revoking Otsuka Pharmaceuticals’ patent extension for an injectable version of antipsychotic drug Abilify, finding the patent expired last year.